Horizon Pharma PLC (NASDAQ:HZNP) has announced that it has received a notice of allowance from the U.S. Trademark and Patent Office. It is a well-known specialty biopharmaceutical company with the primary objective of improving the lives of patients by offering different products and services.
Management’s Call On The Notice of Allowance:
Horizon Pharma is active in developing, identifying, commercializing, and acquiring various products that address peculiar medical needs in today’s time. As per the reports, it has received a notice from U.S. Trademark and Patent Office for the U.S. patent titling “Diclofenac Topical Formulation” and application number 14/596,813. It covers PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), which is a U.S. government approved product of Horizon.
The entire senior management team of the company is delighted about this notice. According to Timothy P. Walbert, President, Chairman and Chief Executive Officer, Horizon Pharma, it’s a positive step for the company. The notice of allowance is an evidence of company’s current position and its initiatives towards strengthening the PENNSAID 2% patent estate. The Notice of Allowance supports the innovation and hard work put in by the company to develop this second to none medicine for all the patients that require it badly.
The primary impact of this Notice of Allowance will be on the substantive examination of the application of the patent. It will lead to the issuance of U.S. process once the administrative proceedings are completed. As per the reports, the U.S. patent, which is supposed to be issued in a few days’ time, will expire in year 2027.
Once the issuance is received, Horizon plans to list this patent in the drug products category in Orange Book or Therapeutic Equivalence Evaluations that has got approval from FDA. If everything goes fine, it will be the eighth U.S. patent that will get listed in the Orange Book for PENNSAID.
